Annovis Bio Narrows Q3 Loss, Raises Capital Amid Going Concern Doubts

TL;DR

**Annovis Bio's cash raise is a band-aid on a bullet wound; the 'going concern' warning means this stock is a high-risk gamble on clinical trial success.**

AI Summary

Annovis Bio, Inc. reported a net loss of $7,262,658 for the three months ended September 30, 2025, a significant improvement from the $12,638,357 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $19,019,785, slightly higher than the $18,725,716 loss in the prior year. Research and development expenses increased to $6,291,171 for the three months ended September 30, 2025, up from $2,689,561 in 2024, reflecting continued investment in its lead product candidate, buntanetap. General and administrative expenses decreased to $1,143,804 for the three months ended September 30, 2025, from $1,698,050 in 2024. The company's cash and cash equivalents stood at $15,286,399 as of September 30, 2025, an increase from $10,551,916 at December 31, 2024, primarily due to $21,427,151 in proceeds from common stock issuances. Despite these capital raises, management concluded that substantial doubt exists about the company's ability to continue as a going concern, citing insufficient cash to fund operations for the next year.

Why It Matters

Annovis Bio's ability to narrow its quarterly net loss and raise over $21 million in new capital is a mixed signal for investors. While the capital infusion provides a temporary lifeline, the explicit 'going concern' warning from management underscores the precarious financial position of this clinical-stage biopharma. For employees, this raises job security concerns, and for patients awaiting treatments for Alzheimer's and Parkinson's, the company's financial instability could impact the future of buntanetap. Competitively, Annovis Bio faces intense pressure in the neurodegeneration space, and its financial health directly impacts its ability to advance clinical trials against larger, better-funded rivals.

Risk Assessment

Risk Level: high — The company explicitly states, "Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern" due to insufficient cash to fund operations for one year after the filing date. This is evidenced by an accumulated deficit of $153.9 million as of September 30, 2025, and a net loss of $19.0 million for the nine months ended September 30, 2025.

Analyst Insight

Investors should approach ANVS with extreme caution, recognizing the significant 'going concern' risk. While the recent capital raise provides some liquidity, the long-term viability hinges entirely on successful clinical trial outcomes for buntanetap and further substantial financing. Only investors with a high-risk tolerance and a deep understanding of speculative biopharma investments should consider a position.

Financial Highlights

debt To Equity

0.31

revenue

$0

operating Margin

-100.0%

total Assets

$17,188,961

total Debt

$4,032,797

net Income

$-7,262,658

eps

$-0.37

gross Margin

N/A

cash Position

$15,286,399

revenue Growth

N/A

Key Numbers

• $15.3M — Cash and Cash Equivalents (Increased from $10.5M at Dec 31, 2024, but still insufficient to fund operations for one year.)
• $19.0M — Net Loss (9 months) (Slightly higher than $18.7M in prior year, indicating continued burn rate.)
• $153.9M — Accumulated Deficit (Highlights significant historical losses and ongoing financial challenges.)
• $21.4M — Proceeds from Stock Issuance (Primary source of capital, crucial for current liquidity but dilutive.)
• $6.3M — R&D Expenses (Q3) (Increased from $2.7M in Q3 2024, showing accelerated clinical development.)
• 26,502,889 — Outstanding Common Shares (As of November 12, 2025, reflecting recent equity issuances and dilution.)

Key Players & Entities

• Annovis Bio, Inc. (company) — registrant
• buntanetap (product) — lead product candidate for neurodegeneration
• Securities and Exchange Commission (regulator) — filing oversight
• $15,286,399 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $19,019,785 (dollar_amount) — net loss for the nine months ended September 30, 2025
• $153,869,247 (dollar_amount) — accumulated deficit as of September 30, 2025
• $21,427,151 (dollar_amount) — proceeds from issuance of common stock, net, for nine months ended September 30, 2025
• Alzheimer's disease (disease) — neurodegeneration target for buntanetap
• Parkinson's disease (disease) — neurodegeneration target for buntanetap
• New York Stock Exchange (regulator) — exchange where ANVS common stock is registered

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has a history of net losses and negative cash flows from operations. As of September 30, 2025, Annovis Bio had $15.3 million in cash and cash equivalents, which management concluded is insufficient to fund operations for the next year, raising substantial doubt about its ability to continue as a going concern.
• Dependence on Capital Raises [high — financial]: The company's primary source of capital has historically been the issuance of common stock and warrants. While $21.4 million in proceeds from common stock issuances in the nine months ended September 30, 2025, increased cash, this reliance indicates potential dilution for existing shareholders and the ongoing need for external financing.
• Clinical Development Risks [high — operational]: Annovis Bio is a clinical-stage drug platform company. There is no assurance that its research and development projects, including its lead candidate buntanetap, will be successful, obtain necessary regulatory approval, or become commercially viable. This inherent risk is common for companies in this sector.
• Reliance on Key Personnel [medium — operational]: The company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Loss of key personnel could significantly impact research and development progress and overall operations.
• Regulatory Approval Uncertainty [high — regulatory]: The success of Annovis Bio's product candidates hinges on obtaining necessary regulatory approvals. Delays or failures in the regulatory process for buntanetap, targeting neurodegenerative diseases like Alzheimer's and Parkinson's, pose a significant risk to the company's future.
• Competitive Landscape [medium — market]: The company operates in the highly competitive pharmaceutical industry, particularly in the neurodegeneration space. The success of buntanetap will be measured against existing treatments and other pipeline candidates from numerous competitors.

Industry Context

Annovis Bio operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on treatments for neurodegenerative diseases. This field is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies in this space often rely on external financing and strategic partnerships to advance their pipelines.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Annovis Bio faces stringent regulatory scrutiny from bodies like the FDA. The success of its lead candidate, buntanetap, is contingent upon successful clinical trials and subsequent regulatory approval, which carries inherent risks of delays or rejection.

What Investors Should Do

1. Monitor cash burn rate and future financing needs closely, given the going concern disclosure.
2. Evaluate the progress and clinical trial results for buntanetap as key catalysts for potential valuation changes.
3. Assess the dilution impact of any future equity issuances required to fund operations.
4. Consider the competitive landscape and potential market penetration for buntanetap if approved.

Key Dates

• 2025-09-30: Balance Sheet Date — Reported $15.3M in cash and cash equivalents, but identified substantial doubt about going concern.
• 2025-09-30: Statement of Operations Period End — Reported a net loss of $7.3M for Q3 2025, with R&D expenses increasing significantly to $6.3M.
• 2024-12-31: Previous Balance Sheet Date — Company had $10.5M in cash and cash equivalents.

Glossary

Buntanetap

Annovis Bio's lead product candidate, a small molecule designed to inhibit the translation of multiple neurotoxic proteins to treat neurodegenerative diseases. (Central to the company's development pipeline and future revenue potential.)

Neurodegeneration

The progressive loss of structure or function of neurons, including conditions like Alzheimer's disease and Parkinson's disease. (The therapeutic area Annovis Bio is targeting with its drug candidates.)

Axonal Transport

The process by which nutrients and other essential molecules are moved along the axons of nerve cells. Impaired axonal transport is a hallmark of neurodegenerative diseases. (A key biological mechanism that Annovis Bio's drug candidate aims to improve.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The company has disclosed substantial doubt about its ability to continue as a going concern due to insufficient funds.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any net gains. It represents a negative retained earnings balance. (Indicates the company's history of unprofitability, standing at a deficit of $153.9 million as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Annovis Bio reported a narrower net loss of $7.3 million for Q3 2025 versus $12.6 million in Q3 2024, driven by a significant increase in R&D spending to $6.3 million from $2.7 million, while G&A expenses decreased. The company's cash position improved to $15.3 million from $10.5 million due to stock issuances, but the overall financial health remains precarious, with a going concern warning persisting.

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share ANVS New York Stock Excha

Filing Documents

• anvs-20250930x10q.htm (10-Q) — 1202KB
• anvs-20250930xex31d1.htm (EX-31.1) — 12KB
• anvs-20250930xex31d2.htm (EX-31.2) — 12KB
• anvs-20250930xex32d1.htm (EX-32.1) — 8KB
• 0001104659-25-110393.txt ( ) — 5968KB
• anvs-20250930.xsd (EX-101.SCH) — 45KB
• anvs-20250930_cal.xml (EX-101.CAL) — 32KB
• anvs-20250930_def.xml (EX-101.DEF) — 151KB
• anvs-20250930_lab.xml (EX-101.LAB) — 367KB
• anvs-20250930_pre.xml (EX-101.PRE) — 278KB
• anvs-20250930x10q_htm.xml (XML) — 1082KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements 3 Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 3 4 5 6

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3. Quantitative and Qualitative Disclosure About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

Signatures

Signatures 32 2 Table of Contents PART I FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Annovis Bio, Inc. Balance Sheets September 30, 2025 December 31, (Unaudited) 2024 Assets Current assets: Cash and cash equivalents $ 15,286,399 $ 10,551,916 Prepaid expenses and other current assets 1,902,562 3,373,717 Total assets $ 17,188,961 $ 13,925,633 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,112,026 $ 2,305,974 Accrued expenses 1,621,771 1,575,013 Total current liabilities 3,733,797 3,880,987 Non-current liabilities: Warrant liability 299,000 737,000 Total liabilities 4,032,797 4,617,987 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock - $ 0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $ 0.0001 par value, 70,000,000 shares authorized, 20,187,904 and 14,141,521 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 2,019 1,414 Additional paid-in capital 167,023,392 144,155,694 Accumulated deficit ( 153,869,247 ) ( 134,849,462 ) Total stockholders' equity 13,156,164 9,307,646 Total liabilities and stockholders' equity $ 17,188,961 $ 13,925,633 See accompanying notes to financial statements. 3 Table of Contents Annovis Bio, Inc. (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 6,291,171 $ 2,689,561 $ 16,464,609 $ 14,996,868 General and administrative 1,143,804 1,698,050 3,524,500 4,963,188 Total operating expenses 7,434,975 4,387,611 19,989,109 19,960,056 Operating loss ( 7,434,975 ) ( 4,387,611 ) ( 19,989,109 ) ( 19,960,056 ) Other income (expense): Interest income 152,317 135,430 531,324 205,576 Other financing costs (Note 7) — ( 524,068 ) — ( 1,870,128 ) Change in fair value of warrants (N

Notes to Financial Statements

Notes to Financial Statements (Unaudited) (1) Nature of Business, Going Concern and Management's Plan Annovis Bio, Inc. (the "Company" or "Annovis") was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins, which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company's lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins, thereby impeding the toxic cascade. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical studies in AD and PD patients as well as in pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels, leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected functions. Going Concern Since its founding, the Company has been engaged in organizational activities, including raising capital, as well as research and development activities. The Company has no t generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development.

View Full Filing

View this 10-Q filing on SEC EDGAR